Development of a recombinant immunotoxin for the immunotherapy of autoreactive lymphocytes expressing MOG-specific BCRs

Alexey Stepanov, Alexander Belyy, Igor Kasheverov, Alexandra Rybinets, Maria Dronina, Igor Dyachenko, Arkady Murashev, Vera Knorre, Dmitry Sakharov, Natalya Ponomarenko, Victor Tsetlin, Alexander Tonevitsky, Sergey Deyev, Alexey Belogurov, Alexander Gabibov

Результат исследований: Материалы для журналаСтатьярецензирование

5 Цитирования (Scopus)

Аннотация

Objective: Myelin oligodendrocyte glycoprotein (MOG) is one of the major autoantigens in multiple sclerosis (MS), therefore selective depletion of autoreactive lymphocytes exposing MOG-specific B cell receptors (BCRs) would be beneficial in terms of MS treatment. Results: Using E. coli we generated an efficient protocol for the purification of the recombinant immunotoxin DT-MOG composed of the extracellular Ig-like domain of MOG fused in frame with the catalytic and translocation subunits of diphtheria toxin (DT, Corynebacterium diphtheriae) under native conditions with a final yield of 1.5 mg per liter of culture medium. Recombinant DT-MOG was recognized in vitro by MOG-reactive antibodies and has catalytic activity comparable with wild-type DT. Conclusion: Enhanced pharmacokinetics (mean residence time in the bloodstream of 61 min) and minimized diminished nonspecific toxicity (LD50 = 1.76 mg/kg) of the DT-MOG makes it a potential candidate for the immunotherapy of MS.

Язык оригиналаАнглийский
Страницы (с-по)1-8
Число страниц8
ЖурналBiotechnology Letters
DOI
СостояниеПринято/в печати - 21 апр 2016
Опубликовано для внешнего пользованияДа

ASJC Scopus subject areas

  • Biotechnology

Fingerprint Подробные сведения о темах исследования «Development of a recombinant immunotoxin for the immunotherapy of autoreactive lymphocytes expressing MOG-specific BCRs». Вместе они формируют уникальный семантический отпечаток (fingerprint).

Цитировать